Danish drugmaker Novo Nordisk initiated federal court lawsuits against medical spas and wellness clinics in New York, Texas, Florida and Tennessee.
five medical spas and wellness clinics for allegedly selling cheaper, unauthorized versions of the company's weight loss drugs Ozempic and Wegovy.
The suits accused the spas and clinics of marketing and selling "compounded" drug products that claim to contain semaglutide, the active ingredient in both Ozempic and Wegovy. Compounded drugs are custom-made versions of a treatment that are not approved by the Food and Drug Administration. Novo Nordisk asked the courts for orders blocking the sales of the unauthorized drugs and an unspecified amount of money damages.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk sues clinics allegedly selling copycat versions of Ozempic and WegovyNovo Nordisk says it filed lawsuits against multiple medical spas, weight loss clinics and compounding pharmacies for allegedly selling unauthorized versions of the drugmaker's popular medicines Ozempic and Wegovy.
Read more »
Novo Nordisk cracks down on alleged Ozempic imitationsDrug maker Novo Nordisk on Tuesday sued five wellness spas and clinics in federal court, accusing them of unlawfully peddling what they said were modified...
Read more »
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst saysThe hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to...
Read more »
Why won't your company pay for weight-loss drugs like WegovyInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Company Behind Ozempic Cracks Down on CopycatsThe drugmaker is suing several medical spas, weight-loss clinics and wellness clinics for allegedly offering custom-made versions of Ozempic.
Read more »